Single-Arm Trial of EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Head and Neck Carcinoma Metastatic/Refractory Nasopharyngeal Carcinoma
Latest Information Update: 23 Jan 2026
At a glance
- Drugs LMP2 specific TCR T cells-TCRCure Biotech (Primary)
- Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer
- Focus Adverse reactions
Most Recent Events
- 20 Jan 2026 Actual primary completion date is 15 Jan 2026.
- 20 Jan 2026 Status changed from recruiting to completed.
- 23 Oct 2024 Status changed from suspended to recruiting.